Obital Diseases Science Lab (ODSL)

The ODSL (Ophthalmic Disease and Systemic Laboratory) investigates the molecular mechanisms, risk factors, and novel therapeutic approaches of Graves’ Orbitopathy (GO), an inflammatory eye disease that typically occurs in association with Graves’ disease. In Germany, up to 300,000 people are affected, many of whom develop clinically significant symptoms such as eyelid retraction, exophthalmos, or double vision. Since the underlying mechanisms remain incompletely understood and targeted therapies are still lacking, research on GO is of high clinical and translational relevance.

Our work focuses on cellular and molecular signaling pathways involved in inflammation, tissue remodeling, and fibrosis. Using in-vitro models with primary orbital fibroblasts and myofibroblasts, we study the effects of cytokines, growth factors, and autoantibodies on cell activation, adipogenesis, and fibrotic remodeling. We also investigate the role of thyroid hormones and TSH receptor antibodies (TRAb) in disease progression. Longitudinal analyses of these antibodies provide valuable insights into disease activity and therapeutic response.

In preclinical research, we employ mouse models of Graves’ Orbitopathy to explore new therapeutic strategies. Our studies focus on S1P modulators (e.g., Fingolimod) and TSHR or IGF1R blockers, which can selectively modulate pathological signaling pathways. We further examine how risk factors such as sex, smoking, and physical stress influence immune responses, tissue remodeling, and treatment outcomes. Using lipidomics and metabolomics, we characterize metabolic alterations in orbital tissue and identify potential biomarkers of disease activity and therapy response.

Through close collaboration with the Essen Orbital Center and clinical partners in Ophthalmology and Endocrinology, experimental findings are directly translated into clinical applications. Our extensive data and biobank provide an important foundation for translational projects. The long-term goal of ODSL is to improve the diagnosis and treatment of Graves’ Orbitopathy through national and international collaborations and to contribute to the development of personalized therapeutic approaches in ophthalmology.